REC: CardioClinics最新文献

英文中文

La impresión tridimensional a partir de la ecografía transtorácica en las cardiopatías congénitas

Q4 Medicine

REC: CardioClinics

Pub Date : 2025-04-01 DOI: 10.1016/j.rccl.2025.01.006

Rocío García-Orta , Miguel Morales García , Eduardo Moreno Escobar

引用次数: 0

Creatina, el suplemento de moda en deportistas, ¿útil en insuficiencia cardiaca?

Q4 Medicine

REC: CardioClinics

Pub Date : 2025-04-01 DOI: 10.1016/j.rccl.2025.01.004

Dámaris Carballeira Puentes , David Dobarro , María Melendo-Viu

引用次数: 0

Impacto del síndrome de deleción 22q11.2 en la mortalidad de los pacientes pediátricos con defectos conotruncales corregidos

Q4 Medicine

REC: CardioClinics

Pub Date : 2025-04-01 DOI: 10.1016/j.rccl.2024.12.003

Carlos Alcántara Noguez , Alejandra Contreras-Ramos , Maria Esther Lazcano Melo , Karen Janeth Zúñiga Sánchez , Sergio Ruiz , Patricia Romero Cárdenas , Alejandro Bolio Cerdán , Juan Manuel Vera Canelo

Introduction and objectives

The 22q11.2 deletion syndrome (22q11.2 DS), known as DiGeorge syndrome, is phenotypically associated with conotruncal heart defects. The aim of this review was to evaluate mortality in pediatric patients with corrected conotruncal defects.

Methods

A literature search was conducted in the databases PubMed, ScienceDirect, Google Scholar, and Redalyc databases, covering the last 10 years. Original articles with pediatric population diagnosed with 22q11.2 DS and conotruncal congenital heart defects were included. A statistical analysis of 5 studies was performed, evaluating the odds ratio (OR), 95% confidence intervals (95%CI), and statistical significance using the chi-square test for each exposure variable. The ROBINS-E tool was used to assess the risk of bias.

Results

A total of 18 articles were collected, including a total population of 10 993 patients (3225 with 22q11.2 DS). The most frequent cardiac defect was tetralogy of Fallot (n = 655). The most common intraoperative complications were arrhythmias, and the most common postoperative complications were infections. Mortality in patients with 22q11.2 DS was assessed. The OR was 0.74 (95%CI, 0.38-1.45; P = .38). Heterogeneity test yielded an I² = 66%.

Conclusions

22q11.2 DS is not associated with post-surgical mortality in patients treated for conotruncal congenital heart defects.

{"title":"Impacto del síndrome de deleción 22q11.2 en la mortalidad de los pacientes pediátricos con defectos conotruncales corregidos","authors":"Carlos Alcántara Noguez , Alejandra Contreras-Ramos , Maria Esther Lazcano Melo , Karen Janeth Zúñiga Sánchez , Sergio Ruiz , Patricia Romero Cárdenas , Alejandro Bolio Cerdán , Juan Manuel Vera Canelo","doi":"10.1016/j.rccl.2024.12.003","DOIUrl":"10.1016/j.rccl.2024.12.003","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>The 22q11.2 deletion syndrome (22q11.2 DS), known as DiGeorge syndrome, is phenotypically associated with conotruncal heart defects. The aim of this review was to evaluate mortality in pediatric patients with corrected conotruncal defects.</div></div><div><h3>Methods</h3><div>A literature search was conducted in the databases PubMed, ScienceDirect, Google Scholar, and Redalyc databases, covering the last 10 years. Original articles with pediatric population diagnosed with 22q11.2 DS and conotruncal congenital heart defects were included. A statistical analysis of 5 studies was performed, evaluating the odds ratio (OR), 95% confidence intervals (95%CI), and statistical significance using the chi-square test for each exposure variable. The ROBINS-E tool was used to assess the risk of bias.</div></div><div><h3>Results</h3><div>A total of 18 articles were collected, including a total population of 10993 patients (3225 with 22q11.2 DS). The most frequent cardiac defect was tetralogy of Fallot (n=655). The most common intraoperative complications were arrhythmias, and the most common postoperative complications were infections. Mortality in patients with 22q11.2 DS was assessed. The OR was 0.74 (95%CI, 0.38-1.45; <em>P =66%.</div></div><div><h3>Conclusions</h3><div>22q11.2 DS is not associated with post-surgical mortality in patients treated for conotruncal congenital heart defects.</div></div>","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"60 2","pages":"Pages 97-105"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143858865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

REC: CardioClinics 2024

Q4 Medicine

REC: CardioClinics

Pub Date : 2025-04-01 DOI: 10.1016/j.rccl.2025.01.003

Sergio Raposeiras-Roubín , Elena Díaz-Peláez , Victoria Cañadas-Godoy

引用次数: 0

Pheochromocytoma as a trigger of miocarditis in arrhythmogenic cardiomyopathy 嗜铬细胞瘤是诱发心律失常性心肌病的心肌炎的一个因素

Q4 Medicine

REC: CardioClinics

Pub Date : 2025-04-01 DOI: 10.1016/j.rccl.2024.10.009

Jon Zubiaur , Víctor Fernández Lobo , Gonzalo Martín Gorria , Luis Javier Ruiz Guerrero

引用次数: 0

Calcificación caseosa del anillo mitral: ¿una entidad benigna?

Q4 Medicine

REC: CardioClinics

Pub Date : 2025-04-01 DOI: 10.1016/j.rccl.2024.10.002

Andoni Fernández González, Amaia Martínez León, Betel Olaizola Balboa

引用次数: 0

Efficacy and safety of creatine supplementation in patients with heart failure and reduced ejection fraction: a pilot study

Q4 Medicine

REC: CardioClinics

Pub Date : 2025-04-01 DOI: 10.1016/j.rccl.2024.10.012

José Carlos López-Clemente , Laura Fuertes-Kenneally , José Abellán Huerta , Federico Soria Arcos , Javier González-López , Rosario Mármol Lozano , Juan Antonio Castillo Moreno

Introduction and objectives

Heart failure (HF) poses a significant global health burden. Patients with HF experience reduced exercise tolerance, greatly affecting their quality of life. While creatine monohydrate (CM) improves functional capacity in healthy individuals, its effects in HF patients remain unexplored.

Methods

We conducted an exploratory, prospective, single center, open-label study evaluating the efficacy and safety of 5 g/day CM during 3 months in patients with HF and reduced ejection fraction. Outcomes included functional capacity, health-related quality of life (HRQoL), echocardiographic and laboratory parameters at 3-months and HF decompensations and mortality at 1-year.

Results

A total of 43 patients participated (60.73 ± 11.73 years; 30.43% females). The intervention was safe. Creatinine increased and glomerular filtration rate declined at 3 months but normalized after discontinuing CM. We observed a statistically significant increase in the 6-minute walk test (48.69 ± 32.76; P = .005), a reduction in Borg scale exertion (−1.57 ± −1.73 points; P < .01), and decreased heart rate increment during exercise (−2.43 ± −8.66 bpm; P = .04). HRQoL improved significantly (4.08 ± 12.29 points; P = .03). No changes were found in echocardiographic parameters, HF decompensations, or mortality.

Conclusions

CM supplementation in patients with HF and reduced ejection fraction is safe and could improve functional capacity and HRQoL. Further research is warranted to confirm our results.

{"title":"Efficacy and safety of creatine supplementation in patients with heart failure and reduced ejection fraction: a pilot study","authors":"José Carlos López-Clemente , Laura Fuertes-Kenneally , José Abellán Huerta , Federico Soria Arcos , Javier González-López , Rosario Mármol Lozano , Juan Antonio Castillo Moreno","doi":"10.1016/j.rccl.2024.10.012","DOIUrl":"10.1016/j.rccl.2024.10.012","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Heart failure (HF) poses a significant global health burden. Patients with HF experience reduced exercise tolerance, greatly affecting their quality of life. While creatine monohydrate (CM) improves functional capacity in healthy individuals, its effects in HF patients remain unexplored.</div></div><div><h3>Methods</h3><div>We conducted an exploratory, prospective, single center, open-label study evaluating the efficacy and safety of 5g/day CM during 3 months in patients with HF and reduced ejection fraction. Outcomes included functional capacity, health-related quality of life (HRQoL), echocardiographic and laboratory parameters at 3-months and HF decompensations and mortality at 1-year.</div></div><div><h3>Results</h3><div>A total of 43 patients participated (60.73±11.73years; 30.43% females). The intervention was safe. Creatinine increased and glomerular filtration rate declined at 3 months but normalized after discontinuing CM. We observed a statistically significant increase in the 6-minute walk test (48.69±32.76; <em>P</em>    <.01), and decreased heart rate increment during exercise (−2.43±−8.66bpm; <em>P</em>    =.03). No changes were found in echocardiographic parameters, HF decompensations, or mortality.</div></div><div><h3>Conclusions</h3><div>CM supplementation in patients with HF and reduced ejection fraction is safe and could improve functional capacity and HRQoL. Further research is warranted to confirm our results.</div></div>","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"60 2","pages":"Pages 76-86"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143858971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Factibilidad y precisión de la impresión 3D a través de ecocardiografía transtorácica 3D en pacientes pediátricos

Q4 Medicine

REC: CardioClinics

Pub Date : 2025-04-01 DOI: 10.1016/j.rccl.2024.12.002

Luis Antonio Jiménez Salinas , Clara A. Vázquez Antona , Tomás Efraín Sánchez Pérez , Juan Carlos Barrera de la Torre , Ana Laura Trujeque Ruiz

Introduction and objectives

Three-dimensional (3D) printing applied to cardiology has demonstrated its usefulness, supporting the planning of surgical and interventional procedures, especially for congenital heart disease. Although printed models have been documented using transesophageal echocardiography images, this technique has limitations in small pediatric patients. The objective was to determine the feasibility and accuracy of digital and printed 3D models obtained from the acquisition of transthoracic images in pediatric patients with ventricular septal defect.

Methods

Five pediatric patients with different locations of the defect were studied. Echocardiographic data were extracted, images processed, segmentation conducted, designs optimized, and models printed; the morphology, diameters of the defect, and their spatial relationships were analyzed.

Results

The correlation between the measurements obtained from 3D echocardiography and the digital 3D models and printed models was high (correlation coefficients of 0.953 and 0.952, respectively). The mean absolute difference between the values obtained by 3D echocardiography and the digital 3D models was 0.064 mm, while the mean absolute difference between the values obtained by 3D echocardiography and the printed models was 0.644 mm. There were no statistically significant differences between echocardiography and the models.

Conclusions

3D digital and printed models obtained from transthoracic echocardiographic data in pediatric patients are technically feasible and accurately reflect the morphology, spatial relationships, and dimensions of the different types of ventricular septal defect. However, the visualization of the models may vary according to the location of the defect, with muscle defects being easier to represent compared to perimembranous defects.

{"title":"Factibilidad y precisión de la impresión 3D a través de ecocardiografía transtorácica 3D en pacientes pediátricos","authors":"Luis Antonio Jiménez Salinas , Clara A. Vázquez Antona , Tomás Efraín Sánchez Pérez , Juan Carlos Barrera de la Torre , Ana Laura Trujeque Ruiz","doi":"10.1016/j.rccl.2024.12.002","DOIUrl":"10.1016/j.rccl.2024.12.002","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Three-dimensional (3D) printing applied to cardiology has demonstrated its usefulness, supporting the planning of surgical and interventional procedures, especially for congenital heart disease. Although printed models have been documented using transesophageal echocardiography images, this technique has limitations in small pediatric patients. The objective was to determine the feasibility and accuracy of digital and printed 3D models obtained from the acquisition of transthoracic images in pediatric patients with ventricular septal defect.</div></div><div><h3>Methods</h3><div>Five pediatric patients with different locations of the defect were studied. Echocardiographic data were extracted, images processed, segmentation conducted, designs optimized, and models printed; the morphology, diameters of the defect, and their spatial relationships were analyzed.</div></div><div><h3>Results</h3><div>The correlation between the measurements obtained from 3D echocardiography and the digital 3D models and printed models was high (correlation coefficients of 0.953 and 0.952, respectively). The mean absolute difference between the values obtained by 3D echocardiography and the digital 3D models was 0.064mm, while the mean absolute difference between the values obtained by 3D echocardiography and the printed models was 0.644mm. There were no statistically significant differences between echocardiography and the models.</div></div><div><h3>Conclusions</h3><div>3D digital and printed models obtained from transthoracic echocardiographic data in pediatric patients are technically feasible and accurately reflect the morphology, spatial relationships, and dimensions of the different types of ventricular septal defect. However, the visualization of the models may vary according to the location of the defect, with muscle defects being easier to represent compared to perimembranous defects.</div></div>","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"60 2","pages":"Pages 87-96"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143858864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Desplazamiento de Holter subcutáneo a la cavidad pleural

Q4 Medicine

REC: CardioClinics

Pub Date : 2025-04-01 DOI: 10.1016/j.rccl.2024.10.004

Miguel Cayetano Amores Luque , Cristina Cavestany García-Matres , José Luis Zamorano Gómez , Javier Moreno

引用次数: 0

Recomendaciones para la optimización de la atención a los pacientes tras infarto agudo de miocardio. Proyecto MIMIC

Q4 Medicine

REC: CardioClinics

Pub Date : 2025-04-01 DOI: 10.1016/j.rccl.2024.11.003

José M. de la Torre-Hernández , Guillermo Aldama-López , Rut Andrea , Miguel Corbí-Pascual , Alberto Cordero , María Rosa Fernández Olmo , Xavier García-Moll , Antonio García Quintana , Arantxa Matalí , Miriam Sandín Rollán , Xoana Taboada , Ana Viana Tejedor , Sergio Raposeiras-Roubín

In recent years, efforts in the care of acute myocardial infarction (AMI) have focused on ensuring a rapid response during the acute phase. However, follow-up after hospitalization is essential for adequate recovery and the prevention of future complications. Heart failure following an infarction is a common complication that implies a worse prognosis and a high rate of readmission, increasing the risk of death both in its early phase and in the long term. The Myocardial infarction and heart failure model (MIMIC) project analyzed patient care after an AMI in different healthcare models, with the aim of identifying recommendations for improvement and best practices that contribute to generalizing optimal care models after an AMI, to achieve a better prognosis, a higher quality of life, and a reduction in healthcare costs.

{"title":"Recomendaciones para la optimización de la atención a los pacientes tras infarto agudo de miocardio. Proyecto MIMIC","authors":"José M. de la Torre-Hernández , Guillermo Aldama-López , Rut Andrea , Miguel Corbí-Pascual , Alberto Cordero , María Rosa Fernández Olmo , Xavier García-Moll , Antonio García Quintana , Arantxa Matalí , Miriam Sandín Rollán , Xoana Taboada , Ana Viana Tejedor , Sergio Raposeiras-Roubín","doi":"10.1016/j.rccl.2024.11.003","DOIUrl":"10.1016/j.rccl.2024.11.003","url":null,"abstract":"<div><div>In recent years, efforts in the care of acute myocardial infarction (AMI) have focused on ensuring a rapid response during the acute phase. However, follow-up after hospitalization is essential for adequate recovery and the prevention of future complications. Heart failure following an infarction is a common complication that implies a worse prognosis and a high rate of readmission, increasing the risk of death both in its early phase and in the long term. The Myocardial infarction and heart failure model (MIMIC) project analyzed patient care after an AMI in different healthcare models, with the aim of identifying recommendations for improvement and best practices that contribute to generalizing optimal care models after an AMI, to achieve a better prognosis, a higher quality of life, and a reduction in healthcare costs.</div></div>","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"60 2","pages":"Pages 127-138"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143858871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

REC: CardioClinics

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀